In colorectal and pancreatic cancers, additional co-mutations in KRAS (non-G12C alleles), EGFR, PIK3CA, BRAF, and MAP2K1 are frequently detected at baseline and are linked to primary resistance, underscoring the importance of comprehensive NGS at diagnosis [121,122]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.